Idraparinux (BioDeep_00000184728)

   

human metabolite blood metabolite


代谢物信息卡片


6-({6-[(2-carboxy-4,5-dimethoxy-6-{[6-methoxy-4,5-bis(sulphooxy)-2-[(sulphooxy)methyl]oxan-3-yl]oxy}oxan-3-yl)oxy]-4,5-bis(sulphooxy)-2-[(sulphooxy)methyl]oxan-3-yl}oxy)-4,5-dimethoxy-3-({3,4,5-trimethoxy-6-[(sulphooxy)methyl]oxan-2-yl}oxy)oxane-2-carboxylic acid

化学式: C38H64O49S7 (1528.0561134)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COC1C(OC(C(C1OC)OC)OC2C(C(C(OC2C(=O)O)OC3C(OC(C(C3OS(=O)(=O)O)OS(=O)(=O)O)OC4C(C(C(OC4C(=O)O)OC5C(OC(C(C5OS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O
InChI: InChI=1S/C38H64O49S7/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)

描述信息

D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors
D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins

同义名列表

9 个代谢物同义名

6-({6-[(2-carboxy-4,5-dimethoxy-6-{[6-methoxy-4,5-bis(sulphooxy)-2-[(sulphooxy)methyl]oxan-3-yl]oxy}oxan-3-yl)oxy]-4,5-bis(sulphooxy)-2-[(sulphooxy)methyl]oxan-3-yl}oxy)-4,5-dimethoxy-3-({3,4,5-trimethoxy-6-[(sulphooxy)methyl]oxan-2-yl}oxy)oxane-2-carboxylic acid; 6-({6-[(2-carboxy-4,5-dimethoxy-6-{[6-methoxy-4,5-bis(sulphooxy)-2-[(sulphooxy)methyl]oxan-3-yl]oxy}oxan-3-yl)oxy]-4,5-bis(sulphooxy)-2-[(sulphooxy)methyl]oxan-3-yl}oxy)-4,5-dimethoxy-3-({3,4,5-trimethoxy-6-[(sulphooxy)methyl]oxan-2-yl}oxy)oxane-2-carboxylate; 6-({6-[(2-carboxy-4,5-dimethoxy-6-{[6-methoxy-4,5-bis(sulfooxy)-2-[(sulfooxy)methyl]oxan-3-yl]oxy}oxan-3-yl)oxy]-4,5-bis(sulfooxy)-2-[(sulfooxy)methyl]oxan-3-yl}oxy)-4,5-dimethoxy-3-({3,4,5-trimethoxy-6-[(sulfooxy)methyl]oxan-2-yl}oxy)oxane-2-carboxylic acid; 6-({6-[(2-carboxy-4,5-dimethoxy-6-{[6-methoxy-4,5-bis(sulfooxy)-2-[(sulfooxy)methyl]oxan-3-yl]oxy}oxan-3-yl)oxy]-4,5-bis(sulfooxy)-2-[(sulfooxy)methyl]oxan-3-yl}oxy)-4,5-dimethoxy-3-({3,4,5-trimethoxy-6-[(sulfooxy)methyl]oxan-2-yl}oxy)oxane-2-carboxylate; Idraparinux (sodium); Idraparinux sodium; SANORG 34006; SANORG-34006; Idraparinux



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Pierre-Alexandre Driguez, Pierre Potier, Patrick Trouilleux. Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale. Natural product reports. 2014 Aug; 31(8):980-9. doi: 10.1039/c4np00012a. [PMID: 24705477]
  • Marc Trellu, Jean-Baptiste Fau, Pierre Cortez, Sue Cheng, Isabelle Paty, Emmanuelle Boëlle, François Donat, Ger-Jan Sanderink. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis. British journal of clinical pharmacology. 2013 May; 75(5):1255-64. doi: 10.1111/bcp.12009. [PMID: 23078631]
  • Shari Ghanny, Theodore E Warkentin, Mark A Crowther. Reversing anticoagulant therapy. Current drug discovery technologies. 2012 Jun; 9(2):143-9. doi: 10.2174/1570163811209020143. [PMID: 22023256]
  • Kellie A Vavra, Mark F Lutz, Maureen A Smythe. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. The Annals of pharmacotherapy. 2010 Apr; 44(4):718-26. doi: 10.1345/aph.1m447. [PMID: 20233918]
  • C Veyrat-Follet, N Vivier, M Trellu, C Dubruc, G J Sanderink. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. Journal of thrombosis and haemostasis : JTH. 2009 Apr; 7(4):559-65. doi: 10.1111/j.1538-7836.2009.03298.x. [PMID: 19187079]
  • Job Harenberg, Ingrid Jörg, Yvonne Vukojevic, Gerd Mikus, Christel Weiss. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. European journal of clinical pharmacology. 2008 Jun; 64(6):555-63. doi: 10.1007/s00228-008-0463-0. [PMID: 18283446]
  • Job Harenberg, Christina Giese, Antje Hagedorn, Inge Traeger, Tivadar Fenyvesi. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Seminars in thrombosis and hemostasis. 2007 Jul; 33(5):503-7. doi: 10.1055/s-2007-982081. [PMID: 17629847]
  • Menno V Huisman, Henri Bounameaux. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Seminars in vascular medicine. 2005 Aug; 5(3):276-84. doi: 10.1055/s-2005-916167. [PMID: 16123915]
  • Markus Reiter, Robert A Bucek, Nihat Koca, Jürgen Heger, Erich Minar. Idraparinux and liver enzymes: observations from the PERSIST trial. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2003 Jan; 14(1):61-5. doi: 10.1097/01.mbc.0000046199.72384.ef. [PMID: 12544730]